Fig. 3
From: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Frequency of EULAR response according to the presence of auto-antibodies, the detectability of serum IL-33, and a serum IgG above the upper limit of normal in cohort 1, cohort 2, and the combined cohorts. Results are presented for patients having auto-antibodies and/or elevated serum IL-33 level and/or elevated serum IgG level compared with patients having no auto-antibodies, a non-elevated serum IL-33 and a non-elevated IgG level (referent). anti-CCP anti-cyclic citrullinated peptide antibody, Ig immunoglobulin, IL interleukin, RF rheumatoid factor